Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed
synergistic effect to sorafenib in human colon carcinoma cell lines. Therefore, sorafenib
combined with S-1 might be more effective treatment for patients with advanced HCC than
sorafenib monotherapy. The investigators propose to conduct a phase I study to determine
maximal tolerated dose (MTD) of S-1 in combination with fixed dose of sorafenib in patients
with advanced HCC